We’re diving into the field of molecular biology here, into an area where researchers in Belgium are once again on the cutting, pioneering edge of technology. Were you aware of radioligand therapy before this article? If you weren’t, look at it as a cocktail, and the clues to the ingredients are in the name: this precision treatment combines a radioisotope with a molecule that targets cancerous cells (the ligand) while leaving unimpacted cells intact.
It seems to be the cancer treatment of the future, and Belgian researchers are foreseeing a doubling in demand by 2027, and to accommodate that, several projects are being set up, touching on various domains. Investing in more infrastructure goes without saying, and there’s a plan to reform reimbursement to make the treatment more affordable. Third, they want to expand on communication and ensure better training, and finally plans are in the making for a national clinical research network.
The treatment is currently most often used in prostate cancer, and in neuroendocrine cancers and is seen as a new chances for those whose bodies wouldn’t respond to more traditional forms of cancer treatment.
Source: Focus on Belgium
